UPDATE ON OPEN INDIVIDUAL STOCK POSITIONS
We are exiting $BCRX and $AVAV; please see separate posts for the reasons. We are short on $ACOR with average price of $30.28. Our thesis has not changed in that Ampyra is not a very good drug, although Wall Street has termed it a blockbuster drug. . In the short term, the bulls may be right. For the first time MS patients with difficulty in walking have hope. MS patients, in general tend to be very knowledgeable about new drugs and as such they are likely to demand that neurologists prescribe Ampyra. Anecdotal evidence supports that neurologists will initially cede